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Abstract
Background: Candida albicans has become resistant to the already limited, toxic and expensive
anti-Candida agents available in the market. These factors necessitate the search for new anti-fungal
agents.
Methods:  Sixty-three plant extracts, from 56 Tanzanian plant species obtained through the
literature and interviews with traditional healers, were evaluated for anti-Candida activity. Aqueous
methanolic extracts were screened for anti-Candida activity by bioautography agar overlay method,
using a standard strain of Candida albicans (ATCC 90028).
Results: Twenty- seven (48%) out of the 56 plants were found to be active. Extracts of the root
barks of Albizia anthelmintica and Balanites aegyptiaca, and roots of Plectranthus barbatus showed
strong activity.
Conclusion:  The extracts that showed strong anti-Candida  activity are worth of further
investigation in order to isolate and identify the active compounds.
Background
Numerous studies have shown an association between
increased prevalence of HIV infection and the occurrence
of opportunistic fungal infections [1,2]. Among the differ-
ent HIV-associated fungal infections, oral mucosal lesions
caused by Candida species are by far the most frequent
manifestation [3]. Up to 90% of HIV-infected individuals
suffer at least one episode during the course of their dis-
ease [3], and the incidence and severity of the episodes
increase with decreasing immunity, especially when
CD4+ cell counts fall to levels below 200 cells/mm3 [4].
Candida albicansis the most causative agent, accounting
for more than 90% of cases [5]. However, other Candida
species such as C. glabrata, C. parapsilosis, C. tropicalis, and
C. kruseimay also cause symptomatic oral candidiasis in
HIV-positive individuals [6]. Other fungal infections seen
in HIV-infected individuals include, cryptococcosis due to
Cryptococcus neoformans and aspergillosis due to Aspergillus
flavus, A. fumigatus and A. niger [7,8].
In sub Saharan Africa, where 70% of the world cases of
HIV/AIDS are found [9], oral candidiasis, including
oropharyngeal and oesophageal candidiasis, are very
common, causing significant morbidity among patients.
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Oral candidiasis is usually treated by topical antifungal
agents, which include nystatin, miconazole, fluconazole,
itraconazole and amphotericin B. However, the manage-
ment of Candida infections faces a number of problems
including; limited number of effective antifungal agents
[10], toxicity of the available antifungal agents [10-12],
resistance of Candida to commonly used antifungals [13-
16], relapse of Candida infections [17], and the high cost
of antifungal agents [10-12]. When relapses occur, the
infections tend to be increasingly refractory to treatment.
The difficulties associated with the management of Cand-
ida infections necessitate the discovery of new antifungal
agents, in order to widen the spectrum of activity against
Candida and combat strains expressing resistance to the
available antifungal agents.
Plant-derived natural products may offer potential lead to
new compounds, which could act on these fungi [18].
This paper reports on the screening of 63 aqueous metha-
nol plant extracts for activity against Candida albicans. The
Map of Tanzania showing the regions where plants were collected Figure 1
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extracts were obtained from 56 plant species, belonging to
29 plant families, collected from four regions of Tanzania
including Coast, Dar es Salaam, Morogoro and Tanga.
Screening was achieved by using the bioautography agar
overlay method, which is very convenient, simple and
efficient [19]. The method can also be employed in the
target-directed isolation of the active constituents.
Methods
Plant collection
Plants were collected from four regions, which are in the
eastern part of Tanzania, namely, Coast, Dar es Salaam,
Morogoro and Tanga (Figure 1). The plants included
those reported in the literature [20,21] to be active against
Candida albicans, but which have not been investigated
further to identify the active compounds. The second cat-
egory comprised of plants obtained through interviews
with traditional healers.
Interviews with traditional healers
Traditional healers in the four regions of Tanzania (Figure
1) were interviewed on plants they used to treat Candida
infections. Symptoms of the various forms of Candida
infections associated with HIV/AIDS were described to the
traditional healers so as to enable them give the appropri-
ate plants they used in the management of these condi-
tions. The symptoms which have been described in the
literature [22] include; oral thrush, mouth ulcers and
lesions of epithelial cells of the lips, erythematous lesions
on the dorsum of the tongue and angular cheilitis. Those
for Candida oesophagitis were painful swallowing, a feel-
ing of obstruction on swallowing, substernal chest pain
and discrete ulceration of the oesophagus [23]. The symp-
tom for vaginal candidiasis was a cuddle milk discharge
[24].
Prior to the interview each traditional healer was asked to
sign an agreement/consent form if she/he agreed with the
terms given in the forms. The form, in short, explained the
importance of the information they were providing and
the type of research that was to be done on the plants they
provided. They were also informed that the results and
any profitable outcome would be communicated to them.
This was done in order to safeguard the interests of both
the parties.
Identification of the plants
Preliminary identification of the plants was done in the
field by a botanist. Herbarium specimens were prepared
and photographs were taken to aid in the confirmation of
the identity of the plants. Voucher specimens were depos-
ited in the Herbarium of the Botany Department, Univer-
sity of Dar es Salaam, Tanzania, where identity of the
plants was confirmed by comparison with available
voucher specimens.
Processing of the plant materials
The plant materials were sorted, washed and chopped
into smaller pieces, where necessary, before drying. The
materials were dried outdoors; however, leaves were dried
in the sun for one day, then in the shade. The dried plant
materials were ground to various degrees of fineness
depending on their botanical structures. This was done
using a Fitz mill Type 6 (Manesty machines Ltd. Liverpool,
England).
Screening of the extracts for anti-Candida activity
Preparation of extracts and standards
Ground plant materials (100 to 200 g) were macerated
with 80% methanol at room temperature (28°C). In each
case the amount of solvent used was just enough to cover
the plant materials. Maceration was carried out for two
days and the procedure was repeated three times. Extracts
were decanted then filtered using filter funnels fitted with
Whatman No 1 filter papers. The extracts were pooled and
concentrated using a Büchi rotary evaporator (Büchi
Labortechnik, Flawil, Switzerland) set at 40–50°C, fol-
lowed by freeze-drying using the Edwards freeze drier
(Edwards High Vacuum International Crawley, Sussex,
England). For each extract 1 g was weighed and dissolved
in 5 ml of methanol to produce a solution with a concen-
tration of 200 µg/µl.
Amphotericin B (Calbiochem, USA and Canada) was used
as the standard anti-fungal agent.
Inoculum
Sabouraud dextrose agar (SDA; Biotec Laboratories Ltd.
UK) was used to prepare the culture medium according to
the manufacturer's directions. Candida albicans ATCC
90028 (provided by Prof. Paul Verweij, Department of
Medical Microbiology, University Medical Center, St. Rad-
boud Hospital, Nijmegen, The Nertherlands) was asepti-
cally inoculated on petridishes containing autoclaved,
cooled and settled medium. The petridishes were incu-
bated at 31°C for 48 h to give white round colonies
against a yellowish background. These were aseptically
sub-cultured on SDA slants.
Candida albicans colonies from SDA slants were sus-
pended in sterilised 0.9% sodium chloride solution (nor-
mal saline), which was compared with a 5 McFarland
solution. The microbial suspension (1 ml) in normal
saline was added to 74 ml of sterile medium, kept at
45°C, to give concentration of 2 × 107 cells/ml.
Bioautography agar overlay
Preamble
The bioautography agar overlay method is an improved
version of a disc diffusion method. Unlike the ordinary
diffusion method in which the drug to be evaluated isBMC Complementary and Alternative Medicine 2006, 6:11 http://www.biomedcentral.com/1472-6882/6/11
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Table 1: TLC Bioautography results of various extracts.
S/N Botanical Name Family Source Plant part % Yield of 
the Extract
Mobile 
Phase
Average 
hRrf value
Average 
inhibition 
zones in mm
1 Abrus precatorius L. Fabaceae T L 18.3 3 - -
2 Acacia nilotica (L.) Del. Fabaceae T Rb 16.5 3 63 < 4
75 < 4
85 < 4
3 Acacia zanzibarica (S. Moore) Taub. Fabaceae T Rb 12.5 2 - -
4 Agathisanthemum bojeri Klotzsch Rubiaceae T Ap 6.5 3 - -
5 Agathisanthemum bojeri Klotzsch Rubiaceae T R 16.0 4 80 < 4
100 10
6 Albizia anthelmintica Brongn Fabaceae T Rb 9.0 5 25 15
40 4
50 5
60 6
7 Allophyllus africanus P. Beauv. Sapindaceae T Ap 3.0 3 - -
8 Asparagus africanus Lam. Liliaceae Lit* Ap 16.4 2 0 < 4
50 < 4
75 < 4
9 Balanites aegyptiaca (L.) Delile Zygophyllaceae T Rb 22.0 5 30 13
10 Bonamia mossambicensis Klotzsch Convolvulaceae Lit* R 6.0 3 - -
11 Boscia salicifolia Oliv. Capparaceae Lit* L 14.5 4 - -
12 Bridelia cathartica Bertol. Euphorbiaceae Lit* Sb 10.0 2 - -
13 Cajanus cajan (L.) Millsp Fabaceae T L 8.0 3 37 4
53 10
78 10
14 Carica papaya L. Caricaceae T R 6.0 3 - -
15 Cassia abbreviata Oliv Fabaceae T Rb 11.5 1 - -
16 Cassia auriculata L. Fabaceae Lit* Sb 10.0 4 60 10
85 8
17 Catunaregum nilotica (Stapf) Tier. Rubiaceae T Rb 6.0 3 0 < 4
40 < 4
55 < 4
80 < 4
18 Ceiba pentandra Gaertn Bombacaceae Lit* L 5.5 3 - -
19 Chassalia umbraticola Vatke Rubiaceae T Rb 6.0 3 0 5
80 6
20 Clutia abyssinica Jaub. & Spach Euphorbiaceae T L 9.5 1 - -
21 Combretum molle R. Br. Combretaceae T R 13.5 4 33 7
48 4
22 Combretum zeyheri Sond Combretaceae Lit* L 3.5 3 46 9
61 6.5
23 Crabbea velutina S. Moore Acanthaceae T W 8.0 3 - -
24 Deinbollia borbonica Scheff Sapindaceae Lit* R 5.0 3 - -
25 Dichrostachys cinerea (L.) Wight & Arn Fabaceae T L 12.0 1 - -
26 Dictyophleba lucida (K. Schum.) Pierre Apocynaceae Li L 13.0 2 10 5
40 5
85 <4
27 Ehretia amoena Klotzsch Boraginaceae T Sb 6.5 3 - -
28 Elaeodendron buchananii (Loes) Loes Celastraceae T Rb 13.5 3 - -
29 Eriosema psoraleoides (Lam.) G. Don Fabaceae Li Sb 4.5 3 - -
30 Flueggea virosa (Roxb. ex Wild.) Voigt. Euphorbiaceae Lit** S 2.5 3 - -
31 Harrisonia abyssinica Oliv. Simaroubaceae Lit*&T Rb 12.5 1 90 10
32 Harrisonia abyssinica Oliv. Simaroubaceae Lit* Ap 10.5 1 - -
33 Hibiscus micranthus L. f. Malvaceae Lit* Ap 3.5 3 - -
34 Holarrhena febrifuga Klotzsch Apocynaceae Lit* L 13.0 5 45 10
35 Lannea stuhlmannii Engl. Anacardiaceae T R 9.5 3 - -
36 Margaritaria discoidea (Baill) G.L. 
Webster
Euphorbiaceae T R 15.0 3 50 5
60 4
37 Ocimum suave Willd Lamiaceae T R 5.5 3 - -BMC Complementary and Alternative Medicine 2006, 6:11 http://www.biomedcentral.com/1472-6882/6/11
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adsorbed on a paper disc and placed onto the inoculated
petridish, in the bioautography agar overlay method the
drug to be evaluated is adsorbed onto the Thin Layer
Chromatography (TLC) plate and the inoculum is laid
onto the plate as a very thin layer of about 1 mm in thick-
ness. In both cases the drug diffuses from the adsorbent
into the inoculum where it exerts its effects. The bioautog-
raphy agar overlay method is advantageous in that, firstly
it uses very little amount of sample when compared to the
normal disc diffusion method and hence it can be used for
bioassay- guided isolation of compounds, and secondly,
since the crude extract is resolved into its different compo-
nents it simplifies the process of identification and isola-
tion of the active compounds [19].
Bioautography agar overlay process
Five microliters (5 µl) of the solution of each extract was
applied on a glass backed Silica gel G60 F254 TLC plates (20
× 20 cm, 250 µm thickness, Merck, Darmstadt, Germany)
and reference plate was similarly prepared. Both plates
were developed to a distance of about 10 cm in the same
tank using the pre-determined mobile phases. The mobile
phase was removed from the plate by drying with a stream
of cool air from a heating gun. The reference plate was
observed in UV light to see if the separated spots were UV
active after which it was sprayed with vanillin sulphuric
acid followed by heating using a heating gun.
The positive control, amphotericin B (0.002 µg/µl) equiv-
alent to 0.01 µg per spot was applied on the test plate in
38 Ozoroa insignis Delile (from Morogoro) Anacardiaceae T Rb 11.5 1 - -
39 Ozoroa insignis Delile (from Tanga) Anacardiaceae T Rb 9.0 3 - -
40 Phyllanthus reticulatus Poir Euphorbiaceae Lit* Ap 11.5 1 - -
41 Physalis peruviana L. Solanaceae T L 13.6 1 0 7
45 6
80 < 4
42 Plectranthus barbatus Andrews Lamiaceae T R 5.5 3 72 12.5
43 Plectranthus barbatus Andrews Lamiaceae T L 2.0 1 85 7
44 Pseudolachnostylis maprouneaefolia Pax Euphorbiaceae Lit* S 12.0 4 - -
45 Pseudolachnostylis maprouneaefolia Pax Euphorbiaceae Lit* R 12.0 1 - -
46 Pseudovigna argentea (Willd) Verde Fabaceae T L 4.0 3 Sf <4
47 Salvadora persica L. Salvadoraceae T Rb 8.5 3 80 10
48 Sclerocarya birrea (A. Rich) Hochst Anacardiaceae T Rb 9.0 3 - -
49 Securidaca longepedunculata Fres. Polygalaceae T Rb 26.5 3 72 < 4
85 < 4
50 Sida serratifolia L. Malvaceae Lit* Ap 4.0 1 85 10
51 Suregada zanzibariensis Baill. Euphorbiaceae T L 8.0 1 0 10
80 5
100 < 4
52 Synoptolepis kirkii Oliv Thymelaeaceae T R 5.7 3 - -
53 Tetracera boiviniana L. Dilleniaceae T L 4.0 3 - -
54 Uvaria acuminata Oliv. Annonaceae T R 7.0 3 70 7
55 Vitex fischeri Gürke Verbenaceae Lit* Rb 6.0 3 52 < 4
65 < 4
56 Xeroderris stuhlmannii (Taub) 
Mendonca
Fabaceae Lit* Sb 6.5 3 - -
57 Ximenia americana L. (from Morogoro) Olacaceae T Rb 18.5 4 - -
58 Ximenia americana L. (from Tanga) Olacaceae T Rb 8.5 4 - -
59 Zanha africana (Radlk.) Exell. Sapindaceae T R 6.5 3 11 4
41 5
60 Zanthoxylum chalybeum Engl. Rutaceae Lit* Rb 9.0 4 30 < 4
85 < 4
61 Ziziphus abyssinica Hochst. ex A. Rich. Rhamnaceae Lit* L 11.5 6 37 9
62 Ziziphus abyssinica Hochst. ex A. Rich. Rhamnaceae Lit* Sb 9.0 3 - -
63 Ziziphus mucronata Willd Rhamnaceae T R 8.0 3 75 < 4
Key:
Ap: aerial parts; L: leaves; Lit: literature; R: roots; Rb: root bark; S: stem; Sb: stem bark; Sf: several faint spots, T: traditional healer; W: whole plant, -: no 
inhibition, *Sawhney et al. (20), **Khan et al. (21),
Mobile phases
1: Chloroform: Methanol 9:1
2: Chloroform:Methanol 5:1
3: Chloroform:Methanol 4:1
4: Chloroform:Methanol:Ethylacetate 4:1:1
5: Chloroform:Methanol:Ethylacetate:water 28:30:35:5
6: Dichloromethane:Methanol:Water 30:10:1
Table 1: TLC Bioautography results of various extracts. (Continued)BMC Complementary and Alternative Medicine 2006, 6:11 http://www.biomedcentral.com/1472-6882/6/11
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triplicate followed by removal of solvent using a stream of
cold air. About 22 ml of the freshly prepared inoculum
described above was uniformly spread using a sterile Pas-
teur pipette. After solidification the plates were placed in
a polythene container lined at the bottom, with moist cot-
ton wool. The plates were incubated at 31°C for 18 to 24
h, after which they were removed and sprayed with an
aqueous solution (2.5 mg/ml) of thiazolyl blue (3-(4,5
dimethylthiazolyl-2)-2, 5-diphenyl tetrazolium bromide)
(MTT) (BDH, Poole England). They were incubated for a
further 4 h, after which the inhibition zones appeared col-
ourless against a purple background. Spots showing any
inhibition were noted and their hRf values and inhibition
zones measured. The test was performed in duplicate.
Results and discussion
The plants studied gave aqueous methanolic extracts with
yields ranging from 2 to 26.5% (Table 1). Twenty-eight
out of the sixty-three extracts, belonging to 27 plant spe-
cies and constituting 48% of all the plants collected, could
be resolved into TLC spots exhibiting activity against C.
albicans (Table 1). The number of active resolved spots for
each extract ranged from 1 to 4. Table 1 shows the TLC
bioautography results for the various extracts developed
using various solvent systems and Figures 2, 3, 4 show the
bioautograms of some of the most active extracts.
Bioautography agar overlay method is considered as one
of the most efficient methods for the detection of antimi-
crobial compounds [19]. It involves the transfer of the
active compounds from the stationary phase into the agar
layer through a diffusion process. From Table 1 it can be
seen that a total of 27 plants, screened by using this
method, exhibited anti-Candida activity. However, only 8
out of the 18 plants previously reported to be active by
Sawhney et al. [20], were found to be active in this bio-
assay. Ziziphus abyssinica and Asparagus africanus which
were collected as substitutes for Ziziphus pubescens and
Asparagus falcatus respectively (reported active by Sawh-
ney et al. [20] were also found to be active. This proves the
fact that allied species may contain similar or related
active compounds [25]. Eriosema psoraleoides, a plant,
reported by Khan et al. [21] to be active was found to be
inactive in this bioassay.
No obvious reasons can be given as to why some of the
plants reported previously to be active were found inactive
in this study. The plant parts used were more or less simi-
lar, with very few peculiar exceptions, such as Xerroderris
stuhlmanii, which Sawhney et al. [20] reported that the
whole plant was active. However this plant is a tree, and,
in this study only the stem barks was evaluated. The bio-
assay method employed in this study is quite different
from the one used by Sawhney et al. [20]. In the present
study the bioautography method was used on partially
resolved extracts, whereas Sawhney et al. [20] used the
agar dilution method for unresolved crude extracts. Also it
was not possible to compare concentrations because in
Chromatograms (i) and bioautograms (ii) for Holarrhena febrifuga leaves (a), Balanites aegyptiaca root bark (b) and Albizia  anthelmintica root bark (c) Figure 2
Chromatograms (i) and bioautograms (ii) for Holarrhena febrifuga leaves (a), Balanites aegyptiaca root bark (b) and Albizia 
anthelmintica root bark (c). Mobile phase: Chloroform:Methanol:Ethylacetate:water 28:30:35:5; Amphotericin B (A)BMC Complementary and Alternative Medicine 2006, 6:11 http://www.biomedcentral.com/1472-6882/6/11
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the bioautography method absolute amounts of extracts
were chromatographed while in the agar dilution method
concentrations of the extracts were used. Such differences
could have contributed to the observed differences in the
bioassay results.
Eighteen (49%) out of 37 plants, obtained through inter-
viewing traditional healers, were found active in this bio-
assay. Ten of these have also been reported to be active in
previous studies; these include; Ziziphus mucronata [26],
Cajanus cajan [27], Acacia nilotica [28], Harrisonia abyssi-
Chromatograms (i) and bioautograms (ii) for Combretum zeyheri leaves (d), Plectranthus barbatus roots (e) and Vitex fischeri root  bark (f) mobile phase: Chloroform: Methanol 4:1 3; Amphotericin B (A) Figure 3
Chromatograms (i) and bioautograms (ii) for Combretum zeyheri leaves (d), Plectranthus barbatus roots (e) and Vitex fischeri root 
bark (f) mobile phase: Chloroform: Methanol 4:1 3; Amphotericin B (A).
Chromatograms (i) and bioautograms (ii) for Margaritaria discoidea roots (g), Cajanus cajan leaves (h) and Zanha africana roots  (j) mobile phase: Chloroform: Methanol 4:1 3; Amphotericin B (A) Figure 4
Chromatograms (i) and bioautograms (ii) for Margaritaria discoidea roots (g), Cajanus cajan leaves (h) and Zanha africana roots 
(j) mobile phase: Chloroform: Methanol 4:1 3; Amphotericin B (A).BMC Complementary and Alternative Medicine 2006, 6:11 http://www.biomedcentral.com/1472-6882/6/11
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nica and Zanthoxylum chalybeum [20]. Others were Securi-
daca longepedunculata, [29,30]Salvadora persica [31],
Balanites aegyptiaca [32], Zanha africana [33], Combretum
molle  [21].  Harrisonia abyssinica and Z. chalybeum were
selected through the literature and were also mentioned
by the interviewed traditional healers. Physalis peruviana,
was reported previously as inactive [34], but was found to
be active in this study. The remaining eight active plants,
including  Margaritaria discoidea, Suregada zanzibariensis,
Plectranthus barbatus, Albizia anthelmintica, Securidaca
longepedunculata, Catunaregum nilotica, Pseudovigna
argentea, Agathisanthemum bojeri and Chassalia umbraticola,
were screened for anti- Candida activity for the first time.
Other plants obtained from the traditional healers, which
were reported active previously were found to be inactive
in this study and they include Ozoroa insignis [35], Carica
papaya [26] and Dichrostachys cinerea [28]. The discrepancy
in the results could be due to a number of factors, includ-
ing differences in the plant parts used, extraction solvents,
time of collection of plant materials, geographical loca-
tion of the plants and bioassay methods.
Eleven plants were resolved into several spots showing
large inhibition zones (≥ 10 mm). The plants included
Agathisanthemum bojeri, Albizia anthelmintica,  Balanites
aegyptiaca, Cajanus cajan, Cassia auriculata, Harrisonia abys-
sinica,Holarrhena febrifuga, Plectranthus barbatus, Salvadora
persica, Sida serratifolia and Suregada zanzibariensis. Eight
among these were obtained through interviewing tradi-
tional healers including A. anthelmintica, B. aegyptiaca and
P. barbatus the most active of the screened plants. This
observation shows that ethnomedical information is
important in drug discovery.
Albizia anthelmintica and  Balanites aegyptiaca have been
reported to contain several triterpene saponins and steroi-
dal saponins, respectively [36-38]. Also the extracts of
these plants formed strong foam, with water indicating
that they contain saponins. The presence of saponins in
these plants is also supported by the chromatogram
obtained by visualizing with vanillin-sulphuric acid (Fig
2) in which the probable active compounds gave purple
or blue colour with this reagent, a normal positive test for
triterpenoidal and steroidal saponins respectively [39].
The roots of B. aegyptiaca have, also been reported to con-
tain flavonoids [40]. The root bark of A. anthelmintica was
reported to contain a histamine alkaloid and proteins
[41]. A. anthelmintica was screened for anti-Candida activ-
ity for the first time and, although B. aegyptiaca was
reported to be active in the previous study [32] no identi-
fication of compounds responsible for the activity was
done.
Plectranthus, barbatus another promising plant has been
reported to contain diterpenes [42] and an essential oil
containing α-pinene, myrcene and caryophylene as the
major constituents [43]. The plant has never been evalu-
ated for anti-Candida activity before, and thus, it has been
shown for the first time in this study to have anti-Candida
activity.
Conclusion
Almost 50% of the collected plants were found to be
active against Candida albicans (ATCC 90028) with varied
degrees of activity. About half (49%) of the plants,
obtained by interviewing traditional healers, demon-
strated activity against C. albicans. This study gives an indi-
cation of the efficacy of the plants obtained from the
traditional healers. The results from this study form a
basis for further studies on the active plants so as to isolate
the compounds responsible for the observed anti-Candida
activity.
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